STEPHANIE ROBBINS: Open Payments
NPI 1306449566 · SPRINGDALE, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$521 in 23 payments from 9 companies in 2025. Trend: 2023 $163 · 2024 $297 · 2025 $521
Food & beverage: $521
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 6 | $174 |
| Janssen Pharmaceuticals, Inc | 3 | $84 |
| Otsuka America Pharmaceutical, Inc. | 4 | $75 |
| ABBVIE INC. | 3 | $69 |
| Lundbeck LLC | 2 | $38 |
| Teva Pharmaceuticals USA, Inc. | 2 | $30 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $18 |
| Neurocrine BioSciences, Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
Products named: Auvelity, REXULTI, INVEGA SUSTENNA, VRAYLAR, CAPLYTA, INGREZZA, AUSTEDO XR, TRINTELLIX.
Industry payments across AR — which companies pay providers there.
